Q-omics provides the consensus-scored CCDC175 profile across patient tissues and cancer cell-line models. CCDC175 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCDC175 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CCDC175 RNA expression shows 12,972 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, THCA, and TGCT as cancer lineages where CCDC175 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC175 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC175 survival associations across molecular data types. CCDC175 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC175 RNA expression–survival associations across cancer types. High CCDC175 expression shows unfavorable associations in LIHC, THCA, LGG and CESC, but favorable associations in PAAD and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCDC175 RNA expression.
This table summarizes CCDC175 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC175. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC175 shows lower tumor expression in THCA, KICH, KIRC and LUAD and higher tumor expression in COAD and BRCA. The THCA box plot shows higher CCDC175 RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p < 0.001).
This table shows molecular features associated with CCDC175 in patient tissues and cancer cell lines. In patient samples, CCDC175 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC175 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
